Welcome to our dedicated page for Butterfly Network news (Ticker: BFLY), a resource for investors and traders seeking the latest updates and insights on Butterfly Network stock.
Butterfly Network, Inc. (NYSE: BFLY) is a healthcare and digital health company focused on portable, semiconductor-based ultrasound technology and ultrasound software solutions. The Butterfly Network news feed on Stock Titan highlights company announcements that relate to its handheld ultrasound devices, Ultrasound-on-Chip™ semiconductor platform, enterprise software and AI initiatives.
Investors and healthcare professionals following BFLY news will see updates on financial results and guidance, such as quarterly earnings releases and preliminary revenue expectations furnished through press releases and 8-K filings. These items often include commentary on revenue growth, cash usage, chip development milestones and the progress of enterprise offerings like Compass™ and Compass AI™.
News coverage also features product and platform developments, including launches of new software capabilities such as Compass AI, announcements about AI-enabled clinical tools like Auto B-line Counter or a Gestational Age AI tool, and information about developer-focused initiatives like Butterfly Garden™ and the planned Beam Steering API. These stories provide insight into how Butterfly is expanding its imaging platform and exposing core capabilities to partners and developers.
Another recurring theme in Butterfly Network news is global health and clinical impact. Press releases describe programs in Sub-Saharan Africa involving handheld probes, training and AI tools for obstetric ultrasound, as well as clinical publications that examine how Butterfly’s devices and software can affect workflows, costs and provider economics in hospital systems.
In addition, the BFLY news stream includes capital markets and corporate updates, such as participation in healthcare investor conferences, executive appointments and SEC-reported events like the NYSE’s decision to delist Butterfly’s public warrants while leaving the common stock listing under BFLY unchanged. For readers tracking Butterfly Network, this page offers a consolidated view of operational, financial, technological and regulatory developments as they are publicly disclosed.
Butterfly Network (NYSE:BFLY) has joined the CAD LUS4TB consortium to evaluate AI-assisted point-of-care ultrasound (POCUS) for tuberculosis detection in Sub-Saharan Africa. The project, funded with €10 million from the EU's Global Health EDCTP3, will trial a new AI algorithm using Butterfly's software development platform and portable ultrasound devices.
The study, launching in September, will involve 3,000 adult patients and aims to enable non-radiologist healthcare workers to detect TB using AI-led POCUS. This initiative addresses a critical need in Africa, where 2.5 million people contracted TB in 2022, representing 25% of global cases and over 33% of TB deaths.
Butterfly Network (NYSE:BFLY) announced significant advances in AI-powered aortic screening technology. A new study from Tufts Medical Center, published in European Heart Journal, demonstrated that their machine learning model achieved a 0.94 AUROC accuracy in identifying aortic stenosis using Butterfly iQ+ handheld ultrasound devices.
The company also launched a new Aorta Exam Protocol on their Butterfly ScanLab™ AI-powered education app, designed to train users in scanning abdominal aorta and recognizing normal anatomy. This development aims to improve detection of conditions like abdominal aortic aneurysms and dissections.
The innovations target aortic stenosis, which affects over 13% of Americans aged 75+ and often remains undiagnosed until advanced stages, particularly in underserved populations.
Butterfly Network (NYSE:BFLY) reported its strongest quarterly performance in Q2 2025, with revenue reaching $23.4 million, up 9% year-over-year. The company achieved record gross margins of 64% and reduced quarterly cash burn to $7.1 million.
Key highlights include international revenue growth of 19% to $6.2 million, driven by the iQ3 launch. The company announced upcoming launch of Compass AI software in Q3 and reported progress in Butterfly HomeCare pilot program. Additionally, CFO Heather Getz resigned, with CAO Megan Carlson assuming interim financial leadership.
Butterfly revised its FY2025 guidance to $92-96 million in revenue (15% growth) and improved Adjusted EBITDA loss guidance to $32-37 million.
Butterfly Network (NYSE:BFLY) reported strong Q2 2025 financial results, achieving its highest quarterly revenue of $23.4 million, representing 9% year-over-year growth. The company reached record gross margins of 64% and reduced quarterly cash burn to a historic low of $7.1 million.
Key highlights include U.S. revenue of $17.2 million and international revenue growth of 19% to $6.2 million. The company revised its full-year 2025 guidance to revenue of $91-95 million (13% growth) and improved Adjusted EBITDA loss guidance to $32-37 million.
Additionally, BFLY announced the resignation of CFO Heather Getz, with Chief Accounting Officer Megan Carlson assuming interim financial leadership roles. The company is preparing to launch its next-generation Compass AI software platform in Q3 and advancing its Butterfly HomeCare solution.
Butterfly Network (NYSE:BFLY), a digital health company specializing in portable ultrasound technology, will report its second quarter 2025 financial results on August 1, 2025, before market opens.
The company will host a conference call and webcast at 8:00 AM ET on the same day, featuring CEO Joseph DeVivo and CFO Heather Getz to discuss financial performance and operational progress. The call will be available via webcast and telephone, with replay access until August 15, 2025.
Butterfly Network (NYSE: BFLY), a digital health company specializing in handheld whole-body ultrasound technology, has announced its participation in the William Blair 45th Annual Growth Stock Conference. The company's President, CEO, and Chairman, Joseph DeVivo, will deliver a presentation on June 5, 2025, at 8:00 am CT in Chicago. The presentation will be accessible via live webcast in the Events & Presentations section of Butterfly's investor website, with a replay option available afterward. Investors can arrange one-on-one meetings with Mr. DeVivo through their William Blair representatives.
Butterfly Network (NYSE: BFLY), a digital health company specializing in portable, semiconductor-based ultrasound technology, has scheduled its first quarter 2025 financial results announcement for May 2, 2025 before market opening.
The company will host a conference call and webcast at 8:00 am ET on the same day, featuring Joseph DeVivo, President, CEO and Chairman of the Board, alongside Heather Getz, EVP and Chief Financial and Operations Officer. The call will be available in listen-only mode through the company's Investor Relations website, with telephone access options for both domestic and international callers.
A replay of the call will remain accessible until May 15, 2025.
Butterfly Network (NYSE: BFLY) announced that its Butterfly iQ3 ultrasound device was prominently featured in Episodes 12 and 13 of HBO Max's medical drama 'The Pitt'. The show depicts the device being used in critical trauma scenarios, particularly during a mass casualty event where traditional cart-based ultrasound equipment was replaced with Butterfly's handheld devices.
The episodes showcase the device's versatility in performing EFAST exams, blood flow evaluations, internal bleeding detection, and intracranial pressure assessments. CEO Joseph DeVivo highlighted that Butterfly devices are present in all top 100 U.S. health systems, indicating widespread adoption of the technology.
The unpaid product placement demonstrates Butterfly's growing recognition in healthcare, with the brand name becoming a verb among clinicians, according to VP of Marketing Jennifer Huang. The feature emphasizes the increasing role of Point-of-Care Ultrasound (POCUS) technology across medical specialties.